Business Wire

MIXMOVE

Share
SANDKI 360° powered by MIXMOVE

Skandi Network is the first unified network for healthcare distribution throughout Europe for human & veterinary healthcare products.

The network offers healthcare temperature-controlled transport for parcels and 1 to 5 pallet(s) shipments throughout 25 countries. Skandi Network is composed of 7 members who are all leading healthcare carriers. The main challenge of the network is to operate cross border transport shipments that involve cross docking operations.

Having end-to-end visibility is already a challenge with one carrier but operating multi-county and multi-carrier operations at the same time is even more challenging. As we are transporting temperature sensitive healthcare products, we must guarantee that the products are transported in alignment with the GDP regulation and that temperature is monitored and always guaranteed. It is also important that our customers can have access to that information in real time.” -Rudy Smets, CEO of Skandi Network.

For these reasons, Skandi Network teamed up with MIXMOVE to develop a unique collaborative platform - Skandi 360° - to consolidate all operational and analytical data flows for all shipments going through the network.

One view and one access to the best-in-class healthcare transport network in Europe

Skandi Network is about giving access to the best-in-class healthcare transport network in Europe, working with 7 domestic leading freight forwarders. Skandi 360° will provide a coordinated solution to the market and its different stakeholders, giving them real time access and control of the first pan-European healthcare transport network (having over 4,780 vehicles and 165 temperature-controlled depots).

Connecting to Skandi 360° will allow them to expand, and/or optimise, their own capacities in a consolidated approach.

CO2 emissions reduction

In addition, Skandi 360° will also give an opportunity to reduce the carbon footprint and the cost of ownership throughout the whole transport chain. This includes:

- Consolidation of flows,

- Optimisation of logistics networks via regional distribution centres,

- No additional passive packaging needed in the network,

- And a reduction of damages and product loss during transport thanks to temperature monitoring.

Digitalising Logistics with MIXMOVE

MIXMOVE can integrate a very large amount of information and data coming from different sources and IT systems (like TMS, telematic systems, WMS, ERP). The MIXMOVE technology turns vertical and independent data flows into a flexible and consolidated One view/One access to data, all the way up to parcel/shipment level.

MIXMOVE also makes it possible to combine transport network functionalities and collaborative platform functionalities. This enables the management of the transport network in a lean and efficient way, creating real added value for all users of Skandi Network.

MIXMOVE tailors its technology to suit specific constraints linked to the healthcare transport business, including the regulations around integrating quality management, real-time temperature follow-up (including corrective and preventive actions), and POD’s that include an end-to-end temperature curve.

We have chosen MIXMOVE for their proven expertise in the global supply chain and their proven technology to manage complex transport network operations. They use an advanced cloud-based technology with API connectivity. The MIXMOVE solution offers a capability to connect different systems and different tools (TMS, WMS, telematic systems…) seamlessly to the platform. This is what we needed, first to allow all members to be connected, and second to allow all external stakeholders, such as logistic service providers, to plug themselves into the platform and use our network." – Rudy Smets, CEO of Skandi Network.

About Skandi Network

Skandi Network is the first unified network for healthcare distribution throughout Europe for human & veterinary pharmaceuticals, biomedicals, APIs, temperature sensitive medical devices, diagnostics and general life products that are temperature sensitive. The network provides 2/8°C, 15/25°C and 20°C (in passive packaging) transport services and covers 25 countries thanks to the alliance of 7 leading healthcare carriers : Arra Group (Poland), BHS Logistics (Denmark, Sweden, Norway, Finland, Estonia, Latvia, Lithuania), BL Turkey Biopharma Logistics (Turkey), Eurotranspharma (France, Belgium, the Netherlands, Luxemburg, Spain, Czech Republic, Slovakia and also Germany, Austria and Slovenia via its existing local partner), Movianto (England, Scotland, Wales, Northern Ireland), PHSE (Italy), Rangel Logistics Solutions (Portugal). The aim of Skandi Network is to have members covering 36 countries by 2025. In total, the network members have more than 4,000 employees, operating in more than 4,780 temperature-controlled vehicles, 10 strategic regional consolidation platforms, 165 temperature controlled depots and transporting 14,750,000 temperature controlled shipments per year.

For more information : https://www.skandi-network.com/

About MIXMOVE

MIXMOVE provides a cloud solution supporting logistics by connecting systems, increasing profitability and reducing CO2 emissions.

For more than 10 years, MIXMOVE provides shippers, carriers and logistics service providers, the best customer experience in getting logistics transparency, predictability and resilience.

The main capabilities of the solution are focused on visibility, control and execution of transport & logistics services. Additional capabilities include optimising warehouse operations (like advanced cross-docking), order flow and fulfilment optimisation, planning automatisation, dispatching and routing optimisation.

MIXMOVE mobile applications enable digitalisation and collaboration with drivers. Trusted by customers like 3M, Volkswagen TPS, DHL, DSV, and Gebrüder Weiss, MIXMOVE has a proven track record in delivering high ROI, facilitating collaboration and helping achieve sustainability by improving resource utilisation.

For more information about MIXMOVE: www.mixmove.io

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005252/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thredd Powers Successful Migration of BigPay’s Card Portfolio to Next-Gen Platform26.11.2025 09:00:00 CET | Press release

The transition of millions of cards showcases Thredd’s superior capabilities amid a high-stakes, global trend of sunsetting legacy processing engagements Thredd, the leading next-generation global payments processor, has successfully migrated BigPay’s virtual and physical card portfolio from its previous, legacy processor to Thredd’s next-generation platform, underscoring Thredd’s leadership in complex card portfolio migrations. The migration project, one of several in recent years, included over 2.5 million cards and highlights Thredd’s unique combination of deep migration experience, robust processes, and advanced technology—qualities increasingly critical as the industry faces a wave of modernisation and replatforming. This achievement comes at a pivotal moment for the industry. Industry analysts estimate that retail banks failing to modernise could see 10% to 15% of their payments revenue at risk annually as legacy platforms struggle to keep pace with demands for hyperpersonalizati

With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?26.11.2025 08:00:00 CET | Press release

An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (39%) leaving or considering leaving their roles while undergoing treatment.1 ‘The Impact of Fertility Challenges at Work: International Insights’ survey by Ferring Pharmaceuticals, Fertility Matters at Work and This Can Happen shows that, despite growing awareness of reproductive health, two thirds (67%) who have experienced fertility challenges say that their workplaces do not offer support for employees undergoing fertility treatment, with France the least likely to provide it (88%).1 60% said they were not clearly entitled to time off for fertility appointments, with time recorded as paid leave, unpaid leave or annual leave (26%), and some also reported taking sick leave due to a lack of flexibility (17%).1 With assisted reproduction therapy, including IVF, already accounting for up to 1

Venture Global and Tokyo Gas Announce 20-Year LNG Sales and Purchase Agreement26.11.2025 01:00:00 CET | Press release

Venture Global’s fourth long-term contract with a Japanese company7.75 MTPA of long-term contracts signed by Venture Global to date in 2025 Today, Venture Global, Inc. (NYSE: VG) and Tokyo Gas Co., Ltd announced the execution of a new, long-term liquefied natural gas (LNG) Sales and Purchase Agreement (SPA). Under the SPA, Tokyo Gas will procure 1 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. This deal marks 7.75MTPA of SPAs signed by Venture Global in the last six months. “With nearly 8 MTPA of new long-term commitments signed this year, Venture Global is pleased to build on our commercial momentum through this new partnership with Tokyo Gas,” said Venture Global CEO Mike Sabel. “Tokyo Gas is a pioneer in the LNG industry and leading provider of natural gas to Japan, and we look forward to working with them as we grow our position as a top LNG supplier to Japan. This agreement will contribute significantly to the US-Japan balance of trade o

Airship Study: No-Code Native App Experiences Double Purchase Frequency (+140%), Offering Path to Profitable Holiday Growth26.11.2025 00:08:00 CET | Press release

New research quantifies the massive conversion lift from optimizing native app and web experiences, providing a critical no-code path for retailers to drive profitability Mobile-first customer experience company Airship today released new aggregate data analysis findings showing that no-code native app experiences significantly increase conversion for key lifecycle events and more than double purchase frequency. The Airship "Experience Impact” research, which studied over 1,000 in-app retail experiences and 1.7 billion device sessions, quantifies the impact of optimizing end-to-end customer journeys—not just sending messages—using no-code and AI-powered tools to drive loyalty and retention at scale, leading to sustainable profitability in a volatile economic environment. Key Findings Customers exposed to high-impact no-code native app experiences such as optimized onboarding flows, dynamic surveys, or embedded personalized offers, purchase 140% more frequently than app customers who do

Court Finds That Two Advanced Cell Diagnostics Patents Are Not Infringed by Molecular Instruments’ Proprietary HCR™ RNA-ISH Technology25.11.2025 17:30:00 CET | Press release

Molecular Instruments, Inc. announced today that the Unified Patent Court (UPC) of the European Union has found that Molecular Instruments’ HCR™ RNA-ISH technology does not infringe two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company). In a 2024 lawsuit filed in the UPC (proceedings no. UPC CFI 187/2024), Advanced Cell Diagnostics alleged that Molecular Instruments’ HCR™ RNA-ISH technology infringes European patents (EP) 2,500,439 and 1,910,572. The Court in its judgment of 18 November 2025 has rejected that claim and dismissed all of Advanced Cell Diagnostics' lawsuit, ruling that the patents are not infringed either literally or by equivalence (UPC Judgment). This 2025 UPC judgment follows on the heels of an April 2024 UK judgment in which the High Court of England and Wales had already dismissed an earlier infringement lawsuit by revoking the UK parts of the same two Advanced Cell Diagnostics patents (proceedings no. HP-2022-000026), ruling that they wer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye